Abstract
Introduction:
α-emitting radiopharmaceuticals are increasingly being evaluated as potential cancer therapeutics. In this study, the authors evaluated the distribution of thorium-227 (227Th) and its first daughter nuclide, radium-223 (223Ra), by analyzing tissue activity data from monkey studies from different antibody-based targeted thorium conjugates (hereafter called “conjugates”). This study clarified the extent of elimination by physical decay and redistribution from tissues for both radionuclides.
Methods:
In monkey biodistribution studies for four different conjugates, animals were sacrificed at multiple time points, and organ activities of 227Th and 223Ra were measured by direct γ counting. These values were compared to the maximally expected organ activities based on physical decay as the sole elimination path to evaluate the impact of redistribution from tissues. Whole-body activities in cancer patients, measured with high-purity germanium detectors during a first-in-human study of a CD22-targeting conjugate, were evaluated similarly to determine whether they aligned with the overall patterns seen in tissue data.
Results:
The integrated analysis demonstrated that for all conjugates, the physical decay appeared to be the main elimination path for 227Th without a strong redistribution from organs, whereas 223Ra shows a fast and strong redistribution (≥90%) from most of the tissues except for bone (∼0%) and (large) intestine. The lack of redistribution from bone as well as the high radioactivity in the intestine is consistent with data obtained with 223Ra chloride in monkeys and humans. These findings were independent of the assessed compound, target, dose, and administered activity. The observation in monkeys that physical decay is the main elimination path for 227Th and that 223Ra undergoes a fast additional elimination in a typical tissue was consistent with clinical whole-body radioactivity data.
Conclusions:
The overarching consistency of the findings regarding tissue redistribution of 227Th and 223Ra across different conjugates and the consistency with clinical observations of whole body radioactivity in patients emphasize the importance of considering the potential redistribution of long-lived daughter nuclides of radionuclides used in therapeutic applications in humans.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
